Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | ATM | Q13315 | 2/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | MPI | P34949 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14269887 | 1.00 | ALDH1A1 (0.39) | ALDH1A1MAPTATMCES2PKM | |
| SCHEMBL15677121 | 1.00 | ALDH1A1 (0.39) | ALDH1A1MAPTATMCES2PKM | |
| SCHEMBL9968969 | 0.76 | ALDH1A1 (0.36) | ALDH1A1MAPTATMCES2PKM | |
| SCHEMBL10033709 | 0.76 | USP2 (0.47) | ALDH1A1MAPTATMCES2PKM | |
| SCHEMBL9968974 | 0.72 | ALDH1A1 (0.33) | ALDH1A1MAPTATMCES2PKM | |
| SCHEMBL12038700 | 0.69 | — | — | |
| SCHEMBL12038674 | 0.69 | — | — | |
| SCHEMBL691387 | 0.69 | — | — | |
| SCHEMBL16640727 | 0.68 | HIF1A (0.34) | — | |
| SCHEMBL14751880 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170049908-A1 | EXTRACELLULAR TARGETED DRUG CONJUGATES | CENTROSE LLC (US) | 2017-02-23 | — | — | US | disclosed |
| US-20170049908-A1 | EXTRACELLULAR TARGETED DRUG CONJUGATES | CENTROSE LLC (US) | 2017-02-23 | — | — | US | disclosed |
| US-9427425-B2 | Extracts, fractions and compositions comprising acetogenins and their applications | LAILA NUTRACEUTICALS (IN) | 2016-08-30 | — | — | US | disclosed |
| US-8703723-B2 | Glycoside compounds and pharmaceutical compositions thereof | CENTROSE, LLC (US) | 2014-04-22 | — | — | US | disclosed |
| US-20140056987-A1 | COMPOSITIONS COMPRISING EXTRACTS OR FRACTIONS DERIVED FROM ANNONA SQUAMOSA FOR THE PREVENTION, TREATMENT OR CONTROL OF INFLAMMATORY AND METABOLIC DISORDERS | LAILA NUTRACEUTICALS (IN) | 2014-02-27 | — | — | US | disclosed |
| US-20120201884-A1 | EXTRACTS, FRACTIONS AND COMPOSITIONS COMPRISING ACETOGENINS AND THEIR APPLICATIONS | LAlLA NUTRACEUTICALS (IN) | 2012-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120201884-A1 | EXTRACTS, FRACTIONS AND COMPOSITIONS COMPRISING ACETOGENINS AND THEIR APPLICATIONS | TNF, IFNG, CXCL10 | ALDH1A1 522/4885MAPT 4099/4885ATM 66/4885 |
| US-20140056987-A1 | COMPOSITIONS COMPRISING EXTRACTS OR FRACTIONS DERIVED FROM ANNONA SQUAMOSA FOR THE PREVENTION, TREATMENT OR CONTROL OF INFLAMMATORY AND METABOLIC DISORDERS | TNF, IL6, MT-ATP6 | ALDH1A1 669/4885MAPT 2111/4885ATM 241/4885 |
| US-20170049908-A1 | EXTRACELLULAR TARGETED DRUG CONJUGATES | ENTPD1, ENTPD2, ENTPD3 | ALDH1A1 1286/4885MAPT 2700/4885ATM 3668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.